| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
19,490 |
15,985 |
$1.70M |
| 99199 |
Unlisted special service, procedure or report |
159,553 |
79,983 |
$1.22M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
9,044 |
7,296 |
$513K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
5,573 |
4,622 |
$466K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
4,945 |
4,037 |
$389K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
3,727 |
3,139 |
$315K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
8,213 |
6,811 |
$266K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
12,701 |
10,571 |
$229K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,221 |
966 |
$105K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
12,079 |
9,444 |
$95K |
| D0145 |
Oral evaluation for a patient under three years of age |
2,308 |
1,893 |
$72K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,824 |
2,134 |
$67K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,746 |
1,434 |
$56K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,187 |
984 |
$56K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,499 |
3,035 |
$45K |
| 90474 |
|
2,343 |
1,967 |
$43K |
| 96127 |
|
8,388 |
6,321 |
$32K |
| D1206 |
Topical application of fluoride varnish |
2,306 |
1,876 |
$31K |
| 99381 |
|
382 |
297 |
$30K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
372 |
356 |
$13K |
| 99215 |
Prolong outpt/office vis |
116 |
90 |
$13K |
| 96161 |
|
2,588 |
2,134 |
$9K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
463 |
330 |
$8K |
| 85018 |
|
4,018 |
3,168 |
$6K |
| 87807 |
|
379 |
337 |
$5K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
37 |
26 |
$4K |
| 99408 |
|
160 |
130 |
$4K |
| 92552 |
|
8,966 |
6,913 |
$3K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
26 |
26 |
$2K |
| 94664 |
|
144 |
123 |
$1K |
| 99173 |
|
9,070 |
7,602 |
$1K |
| 90686 |
|
2,297 |
1,982 |
$972.69 |
| 96160 |
|
280 |
228 |
$849.74 |
| 90651 |
|
316 |
244 |
$678.24 |
| 83718 |
|
67 |
58 |
$636.70 |
| 90734 |
|
176 |
142 |
$631.30 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
50 |
48 |
$498.82 |
| 81003 |
|
218 |
183 |
$488.22 |
| 82465 |
|
67 |
58 |
$337.90 |
| 90698 |
|
4,239 |
3,516 |
$323.34 |
| 90680 |
|
2,503 |
2,086 |
$291.36 |
| 90677 |
|
385 |
347 |
$268.63 |
| 80061 |
Lipid panel |
17 |
13 |
$210.55 |
| 90633 |
|
1,851 |
1,536 |
$168.05 |
| 90715 |
|
163 |
124 |
$137.42 |
| 90688 |
|
50 |
44 |
$32.70 |
| 94761 |
|
115 |
89 |
$31.60 |
| 90744 |
|
2,044 |
1,680 |
$27.16 |
| 83655 |
|
116 |
88 |
$14.93 |
| 90619 |
|
342 |
266 |
$0.02 |
| 90670 |
|
4,165 |
3,411 |
$0.00 |
| 90707 |
|
325 |
272 |
$0.00 |
| J7510 |
Prednisolone oral, per 5 mg |
35 |
30 |
$0.00 |
| 90685 |
|
293 |
225 |
$0.00 |
| 90710 |
|
337 |
283 |
$0.00 |
| 90700 |
|
52 |
39 |
$0.00 |
| 90648 |
|
16 |
13 |
$0.00 |
| 99000 |
|
5,422 |
4,509 |
$0.00 |
| 90696 |
|
356 |
300 |
$0.00 |
| 90716 |
|
274 |
238 |
$0.00 |
| 94760 |
|
94 |
86 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
64 |
59 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
52 |
45 |
$0.00 |
| 36416 |
|
53 |
39 |
$0.00 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
18 |
15 |
$0.00 |